Cellid Co.,Ltd. leads development of anti-cancer immunotherapy.
Rapid development of new pipelines
New pipelines can be quickly developed based on CeliVax platform by simply changing the antigens.
Like our current BVAC pipelines, one CeliVax pipeline can target multiple cancer types that express the same tumor antigen. Furthermore, tumors expressing different antigens can also be targeted by CeliVax, as CeliVax can be fitted to any cancer type with an identified antigen.